戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ity to bacterial toxins, and blockade by the B2 receptor antagonist.
2 evented by icatibant, a clinically available B2 receptor antagonist.
3 cell proliferation was also inhibited by the B2 receptor antagonist alone (27%) but not by the NK1 re
4 -NG-nitroarginine methyl ester, a bradykinin B2 receptor antagonist and tetrodotoxin.
5  2009) and icatibant (a selective bradykinin B2 receptor antagonist approved for use in the United St
6 17647 and Hoe 140 (p < 0.05), two bradykinin B2 receptor antagonists, but not by desArg9,[Leu8]bradyk
7 as significantly inhibited by the bradykinin B2 receptor antagonist, d-Arg, [Hyp3, Thi5,8, d-Phe7]-br
8 n inhibitor sebetralstat and oral bradykinin B2 receptor antagonist deucrictibant.
9                              Both bradykinin B2 receptor antagonists had no significant effects on ad
10                     NPC-17731, another kinin B2 receptor antagonist, had similar inhibitory effects o
11                        Hoe 140, a bradykinin B2-receptor antagonist, had no effect on the hypotensive
12  microM) and was abolished by the bradykinin B2 receptor antagonist HOE 140 (1 microM).
13                               The bradykinin B2 receptor antagonist HOE 140 abolished the protective
14  to bradykinin was blocked by the bradykinin B2 receptor antagonist HOE 140, by inhibition of the Ca2
15 rd current response to Bk was blocked by the B2 receptor antagonist HOE-140, which indicates that the
16 itrite production, which were blocked by the B2-receptor antagonist HOE 140.
17 pretreatment of the animal with a bradykinin B2 receptor antagonist (HOE 140).
18 effects of BK pretreatment were blocked by a B2 receptor antagonist (HOE-140; 10 microm) or a protein
19 a specific kinin B1 receptor agonist), kinin B2 receptor antagonists: HOE140 (30 micrograms kg-1 i.v.
20  (b) the ACEi ramipril, with and without the B2 receptor antagonist icatibant (B2-ant); or (c) an AT1
21                                          The B2 receptor antagonist icatibant is approved for treatme
22 (6)-nitroarginine methyl ester or bradykinin B2 receptor antagonist icatibant.
23 s abolished by application of the bradykinin B2-receptor antagonist, icatibant (0.5 mg/kg).
24 ot support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-associated angio
25                      Icatibant, a bradykinin B2 receptor antagonist, is an established treatment for
26                       Deucrictibant, an oral B2 receptor antagonist, is currently under development f
27 bcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label stan
28 -Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D-Arg0-Arg1-
29 h HOE-140 (0.3 mg/kg), a specific bradykinin B2-receptor antagonist, produced no significant alterati
30 ols) was completely blocked by either NK1 or B2 receptor antagonists (SR140333 or FR172357, respectiv
31 ect of B2 receptor blockade using icatibant (B2 receptor antagonist) was studied using a pressure-tar
32 ght to test the hypothesis that a bradykinin B2 receptor antagonist would shorten time-to-resolution